Skip to main content
    P

    Plus Therapeutics Inc (PSTV)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.95
    +0.18 (+23.32%)

    Market Cap: $26.64M

    Last updated: Nov 13, 2026 at 4:00 PM ET

    Plus Therapeutics Inc (PSTV) Competitors

    Updated Nov 13, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Plus Therapeutics are Grace Therapeutics (GRCE), Marker Therapeutics (MRKR) and Gain Therapeutics (GANX). By market cap, Plus Therapeutics ranks 8th of the 13 companies on this page; Gain Therapeutics (GANX) is the largest at $46.31M.

    Peer Comparison

    PSTV's ROIC of -827.8% is below the peer median of -133.0%, and its revenue growth of -2.9% is below the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Plus Therapeutics (PSTV)$26.64MN/A2.0x-230.2%-827.8%-2.9%0.00%
    Grace Therapeutics, Inc. (GRCE)$38.08MN/AN/A0.0%N/A0.0%0.00%
    Marker Therapeutics Inc (MRKR)$14.51MN/A14.5x-245.5%N/A-51.0%0.00%
    Gain Therapeutics Inc (GANX)$46.31MN/AN/A0.0%-170.5%-100.0%0.00%
    Transcode Therapeutics Inc (RNAZ)$22.35MN/AN/A0.0%-412.7%0.0%0.00%
    Lite Strategy, Inc. (LITS)$25.30MN/AN/A0.0%N/A0.0%0.00%
    Pelthos Therapeutics Inc. (PTHS)$29.24MN/A0.5x-199.5%-95.4%0.0%0.00%
    OS Therapies Incorporated (OSTX)$34.87MN/AN/A0.0%218.0%0.0%0.00%
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)$36.15MN/AN/A0.0%N/A0.0%0.00%
    Quince Therapeutics, Inc. (QNCX)$32.27MN/AN/A0.0%N/A0.0%0.00%
    Tvardi Therapeutics, Inc. (TVRD)$15.74MN/AN/A0.0%N/A0.0%0.00%
    NextCure Inc (NXTC)$29.31MN/AN/A0.0%N/A-100.0%0.00%
    Estrella Immunopharma Inc. (ESLA)$22.36MN/AN/A0.0%N/A0.0%0.00%
    Peer median$29.28MN/A7.5x0.0%-133.0%0.0%0.00%
    Market data as of Nov 13, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Plus Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Grace Therapeutics, Inc. (GRCE)
    Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
    GRCE competitors
    Marker Therapeutics Inc (MRKR)
    Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, is dedicated to the development and commercialization of various T-cell-based...
    MRKR competitors
    Gain Therapeutics Inc (GANX)
    Gain Therapeutics, Inc., a developing biotechnology company, is dedicated to developing a variety of therapies to treat diseases caused by protein misfolding.
    GANX competitors
    Transcode Therapeutics Inc (RNAZ)
    TransCode Therapeutics, Inc., a biopharmaceutical company, is dedicated to the development and commercialization of drugs for the treatment of metastatic...
    RNAZ competitors
    Lite Strategy, Inc. (LITS)
    Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of various therapies for the treatment of cancer.
    LITS competitors
    Pelthos Therapeutics Inc. (PTHS)
    Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
    PTHS competitors
    OS Therapies Incorporated (OSTX)
    OS Therapies Incorporated is a pioneering biopharmaceutical company committed to developing innovative treatments for unmet medical needs...
    OSTX competitors
    Telomir Pharmaceuticals, Inc. Common Stock (TELO)
    Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human...
    TELO competitors
    Quince Therapeutics, Inc. (QNCX)
    Quince Therapeutics, Inc., a biopharmaceutical company, is focused on advancing precision therapies for rare and debilitating diseases.
    Tvardi Therapeutics, Inc. (TVRD)
    Tvardi Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company focused on developing novel oncology therapies to meet critical unmet...
    TVRD competitors
    NextCure Inc (NXTC)
    NextCure, Inc., a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of novel immunomedicines to treat cancer and other...
    NXTC competitors
    Estrella Immunopharma Inc. (ESLA)
    Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States.
    ESLA competitors

    Frequently Asked Questions About PSTV

    Who are Plus Therapeutics' main competitors?

    The companies most similar to Plus Therapeutics include Grace Therapeutics (GRCE), Marker Therapeutics (MRKR), Gain Therapeutics (GANX), Transcode Therapeutics (RNAZ) and Lite Strategy (LITS), listed from the closest match.

    Who is Plus Therapeutics' biggest competitor?

    Gain Therapeutics (GANX) is the largest of the similar companies at $46.31M; Grace Therapeutics (GRCE) is the closest match by business profile, size, sector and industry.

    How does PSTV stock compare with its competitors?

    PSTV's P/S is 2.0x against a peer median of 7.5x; its net margin is -230.2% against a peer median of 0.0%.

    Which of Plus Therapeutics' competitors pays a higher dividend?

    Plus Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Plus Therapeutics bigger than its competitors?

    No. Plus Therapeutics is 8th by market cap among the 13 companies on this page; the largest is Gain Therapeutics (GANX) at $46.31M.